Evidence map›Paper›PMID 41943825›Full record

ArticlePeerJ2026

Comparative efficacy of 5-hydroxytryptamine-3 (5-HT3) receptor antagonists with or without dexamethasone for prevention of chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy (HEC): a network meta-analysis.

Hongxia Xu, Jiankun Xing, Shaohui Yang, Lingyan Rong, Lingyan Liu, Xiaotao Chen

Abstract readNetwork Meta-AnalysisComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Article in PeerJ, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Hongxia XuDepartment of Clinical Pharmacy, Wendeng Hospital of Traditional Chinese Orthopedics and Traumatology of Shandong Province, Wendeng District, Weihai City, Shandong Province, China.
Jiankun XingRehabilitation Department, Wendeng Hospital of Traditional Chinese Orthopedics and Traumatology of Shandong Province, Wendeng District, Weihai City, Shandong Province, China.
Shaohui YangDepartment of Clinical Pharmacy, Wendeng Hospital of Traditional Chinese Orthopedics and Traumatology of Shandong Province, Wendeng District, Weihai City, Shandong Province, China.
Lingyan RongDepartment of Clinical Pharmacy, Wendeng Hospital of Traditional Chinese Orthopedics and Traumatology of Shandong Province, Wendeng District, Weihai City, Shandong Province, China.
Lingyan LiuDepartment of Anesthesiology, Wendeng Hospital of Traditional Chinese Orthopedics and Traumatology of Shandong Province, Wendeng District, Weihai City, Shandong Province, China.
Xiaotao ChenDepartment of Anesthesiology, Wendeng Hospital of Traditional Chinese Orthopedics and Traumatology of Shandong Province, Wendeng District, Weihai City, Shandong Province, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: This network meta-analysis evaluated the efficacy of 5-hydroxytryptamine-3 (5-HT3) receptor antagonists, with or without Dexamethasone (D), for preventing chemotherapy-induced nausea and vomiting (CINV) in patients undergoing highly emetogenic chemotherapy (HEC) who were limited to these regimens. Methods: Randomized controlled studies (RCTs) were searched in PubMed, Embase, Cochrane and Web of Science from their inception up to January 28, 2026 (a supplementary search was conducted from April 1, 2025, to January 28, 2026), to identify studies on patients who used 5-HT3 receptor antagonists (with or without Dexamethasone) to prevent nausea and vomiting caused by highly emetogenic chemotherapy. A total of 36 randomized controlled trials (reported in 37 articles) enrolling 11,131 patients were included in this analysis. The outcome measures included acute nausea, acute vomiting, acute complete control, delayed nausea, delayed vomiting and delayed complete control. Results: Palonosetron (P) is generally more effective than first-generation 5-HT3 receptor antagonists (1 Conclusions: Dexamethasone may enhance the efficacy of first-generation 5-HT

Indexed as

AntiemeticsAntineoplastic AgentsDexamethasoneNauseaSerotonin 5-HT3 Receptor AntagonistsVomitingDrug Therapy, CombinationHumansPalonosetronRandomized Controlled Trials as TopicAntiemeticsAntineoplastic AgentsDexamethasonePalonosetronSerotonin 5-HT3 Receptor Antagonists5-HT3 antagonists5-HT3 antagonists (with dexamethasone or not)Highly emetogenic chemotherapyHighly emetogenic chemotherapy-induced nausea and vomitingNausea and vomitingWith dexamethasone or not

Identifiers

PMID41943825
PMCPMC13050518

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.